Analysis of the clinical antibacterial drug pipeline

The clinical antibacterial pipeline is dominated by derivatives of established classes and most development candidates display limited innovation. New antibacterial drugs without pre-existing cross-resistance are under-represented and are urgently needed, especially for geographical regions with high resistance rates among Gram-negative bacteria and M tuberculosis.

This  comprehensive analysis of the global clinical pipeline of antibacterial
drugs presents a catalogue of all antibacterial drugs in clinical development and assesses both their potential activity against the WHO critical priority pathogens for R&D (including Mycobacterium
tuberculosis and Clostridium difficile) as well as their degree of
innovation. This analysis focuses on the assessment of the pipeline against global public health needs, its potential innovation, and clinical value globally.

Analysis of the clinical antibacterial and antituberculosis pipeline.

Theuretzbacher U, Gottwalt S, Beyer P, Butler M, Czaplewski L, Lienhardt C, Moja L, Paul M, Paulin S, Rex JH, Silver LL, Spigelman M, Thwaites GE, Paccaud JP, Harbarth S. Lancet Infect Dis. 2019 Feb;19(2):e40-e50.

Tables